As Chloroquine Demand Surges, Bayer Looks To Emergency Use Authorization To Enter US Market

Unlike diagnostics, EUAs for drugs are rare and the fact that there already are FDA-approved competitors for Bayer’s chloroquine phosphate product may make the decision more complicated.

3D_Coronavirus
Pharma companies are ramping up chloroquine production as Bayer looks to bring its product to the US under an emergency use authorization. • Source: Shutterstock

An ongoing shortage and increasing demand for a potential treatment for coronavirus could allow Bayer AG to obtain a rarely granted emergency use authorization from the US Food and Drug Administration.

Chloroquine phosphate and hydroxychloroquine, each old anti-malaria drugs, are being tested in the US and other countries as potential treatments...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Review Pathways

More from Pathways & Standards